fda semaglutide shortage resolved feb 21 2025 ends as sets deadline for compounders Semaglutide Shortage Ends: Compounded Versions

For GLP-1 users specifically, the challenge is that reduced food intake also means reduced dietary fiber intake

Journal of Pharmacy Technology, 38 (4), 239246.

Nausea, diarrhea, and abdominal pain are frequently reported among users

Most Common Side Effects These are the side effects most frequently reported in clinical studies: Nausea (feeling sick) Vomiting Diarrhoea Constipation Abdominal discomfort or bloating Decreased appetite Fatigue or mild tiredness Headaches These effects are similar to those seen with other weight-loss injections that act on gut hormones and are typically digestive (gastrointestinal) symptoms